☆ 4.6 Meeting Abstract

Sustained Efficacy and Safety of Burosumab, an Anti-FGF23 Monoclonal Antibody, for 88 Weeks in Children and Early Adolescents with X-Linked Hypophosphatemia (XLH)

JOURNAL OF BONE AND MINERAL RESEARCH (2018)

Rate this paper

The primary rating indicates the level of overall quality for the paper. Secondary ratings independently reflect strengths or weaknesses of the paper.

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Sustained Efficacy and Safety of Burosumab, an Anti-FGF23 Monoclonal Antibody, for 88 Weeks in Children and Early Adolescents with X-Linked Hypophosphatemia (XLH)

Rate this paper

Discover Peeref hubs

Publish scientific posters with Peeref

Export Citation

Share Paper